Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants
Lung Cancer Feb 09, 2018
Li Y, et al. - Anaplastic lymphoma kinase (ALK) rearrangements are present in approximately 5% of non-small-cell lung cancers (NSCLCs). Investigation for clinical efficacy of crizotinib in different ALK variants showed prolonged progression-free survival in patients with EML4-ALK variant 2.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
